Filed by Bowne Pure Compliance





Exhibit 10.1




EXECUTIVE EMPLOYMENT AGREEMENT




THIS AMENDMENT NO. 3 TO EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered
into as of June 27, 2008 by and between ImaRx Therapeutics, Inc., a Delaware corporation (the
“Company”), and Bradford A. Zakes (“Executive”) and replaces the Amendment No. 2 to Executive
Employment Agreement between the parties dated January 1, 2008 and its predecessor agreements dated
February 1, 2007 and August 22, 2005 (together, the “Original Agreement”).




WITNESSETH:



WHEREAS, the Company desires to retain the services of Executive, and Executive desires to be
employed by the Company, on the terms and conditions of this Agreement.



NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements set
forth herein, the Company and Executive, intending to be legally bound, hereby agree as follows:



1. Employment. The Company agrees to employ Executive as President and Chief
Executive Officer and Executive accepts such employment and agrees to perform full-time employment
services for the Company, subject to Section 3.2 of this Agreement and the Certificate of
Incorporation and Bylaws of the Company, as presently in effect and as amended from time to time
(the “Organizational Documents”), and the resolutions of the Board of Directors of the Company (the
“Board”), for the period and upon the other terms and conditions set forth in this Agreement.



2. Term. The term of Executive’s employment hereunder (the “Term”) commenced upon the
Executive’s initial employment start date under the Original Agreement and shall continue until
this Agreement is terminated as set forth in Section 5 below.




3. Position and Duties.



3.1 Service with the Company. During the Term of this Agreement, Executive agrees to
perform the duties of President and Chief Executive Officer of the Company and such other duties as
the Board may from time to time prescribe that are consistent with the duties of a President and
Chief Executive Officer of a company of the size and nature of the Company.



3.2 No Conflicting Duties. Executive hereby confirms that he is under no contractual
commitments inconsistent with his obligations set forth in this Agreement, and that during the Term
of this Agreement, he will not render or perform services, or enter into any contract to do so, for
any other corporation, firm, entity or person that are inconsistent with the provisions of this
Agreement or Executive’s fiduciary obligations to the Company. Except as otherwise provided
herein, Executive shall not serve as a director of any other corporation (except nonprofit organizations to the extent such service does not materially affect
Executive’s performance of his duties for the Company) without the prior approval of the Board of
Directors.


 


1









 






4. Compensation and Benefits.



4.1 Retention Bonus Payment. Promptly following execution of this Agreement by each
of the parties hereto, the Company shall pay to Executive a lump sum cash retention bonus payment
in the amount of $290,000. In consideration for such payment, Executive agrees to remain in the
employ of the Company for a period of 12 months from the date of this Agreement. In the event that
Executive’s employment with the Company is terminated prior to the expiration of such 12 month
period and such termination is not incident to one or more of the events provided for in Section 7
(Change-in Control), Section 7.2 (Good Reason), Section 5.1 (Disability),
Section 5.2 (Death of Executive) or Section 5.5 (Without Cause), then Executive
shall repay to the Company that portion of the bonus equal to the product of the total bonus
payment multiplied by the fraction where the numerator is the number of months remaining on
Executive’s 12 month commitment and the denominator is 12.



4.2 Base Salary. (a) As compensation for all services to be rendered by Executive
under this Agreement, the Company shall pay to Executive during the Term an annual base salary of
$275,000 (the “Base Salary”). Subject to Section 4.1(b), the Base Salary shall be reviewed at
least annually and changed at the discretion of the Board (or its Compensation Committee),
provided, however, that the Base Salary may not be decreased without the written consent of the
Executive. The Company shall pay the Base Salary to Executive in accordance with the Company’s
normal payroll procedures and policies.



(b) If Executive’s Base Salary is increased at any time, it shall not thereafter be decreased
during the Term of this Agreement, unless such decrease is the result of a general reduction (on
the same percentage basis) affecting the base salaries of all other executive officers of the
Company and such decrease does not result in a Base Salary of less than the Base Salary set forth
in Section 4.1 above.



4.3 Annual Bonus. With respect to each full fiscal year until the Termination Date,
Executive shall be eligible to receive bonus awards aggregating up to 50% of Base Salary annually,
payable periodically based on the achievement of pre-determined milestones established from time to
time by the Board (or its Compensation Committee) pursuant to the Company’s Bonus Plan (as adopted
by the Board on October 18, 2007 and as such plan may be amended from time to time by the Board, in
its sole discretion).



4.4 Stock Options. (a) The Company has previously granted to Executive various stock
options to purchase shares of the Company’s common stock (the “Shares”), pursuant to the Company’s
2000 Stock Plan and/or the 2007 Performance Incentive Plan (the “Plans”). As a result of the
foregoing grants, the options currently held by Executive are as follows:


 


2









 





	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Grant	 	Tax	 	 	No. of	 	 	Exercise	 	 	% Vested as of	 
	Date	 	Character	 	 	Shares	 	 	Price	 	 	12/31/07	 
	08/22/05
	 	ISO	 	 	24,000	 	 	$	15.00	 	 	 	58	%
	12/14/05
	 	ISO	 	 	4,000	 	 	$	20.00	 	 	 	50	%
	12/12/06
	 	ISO	 	 	30,333	 	 	$	15.00	 	 	 	25	%
	07/31/07
	 	ISO	 	 	41,666	 	 	$	5.00	 	 	 	0	%
	09/07/07
	 	ISO	 	 	16,667	 	 	$	4.05	 	 	 	100	%
	12/18/07
	 	ISO	 	 	225,000	 	 	$	2.10	 	 	 	0	%






4.5 Participation in Benefit Plans. Executive shall be included to the extent
eligible thereunder in any and all plans of the Company providing general benefits for the
Company’s executive employees, including, without limitation, medical, dental, vision, short and
long term disability insurance, life insurance, 401(k) plan, sick days, vacation, and holidays, to
the extent the Company makes such plans or benefits available to its executive employees generally.
Executive’s participation in any such plan or program shall be subject to the provisions, rules,
and regulations applicable thereto. In addition, during the Term of this Agreement, Executive shall
be eligible to participate in all non-qualified deferred compensation and similar compensation,
incentive, bonus, profit sharing and stock plans offered, sponsored or established by Company on
substantially the same or a more favorable basis as any other employee of Company.



4.6 Business Expenses. In accordance with the Company’s policies established from
time to time, the Company will pay or reimburse Executive for all reasonable and necessary
out-of-pocket expenses incurred by him in the performance of his duties under this Agreement,
subject to the presentment of appropriate supporting documentation. During the Term of this
Agreement, the Company shall at its expense provide Executive with reasonable office space and
furnishings (including without limitation desk and lap top computers) at the Company’s principal
executive offices, and a cell telephone.



4.7 Key Man Life Insurance. During the Term of this Agreement, the Company shall have
the option of purchasing and paying the premiums for a “Key Man” life insurance policy relating to
Executive in a coverage amount determined by the Company, and the Company shall be named as the
beneficiary of such policy.




5. Termination.



5.1 Disability. At the Company’s election, Executive’s employment and this Agreement
shall terminate upon Executive’s becoming totally or permanently disabled for a period of ninety
(90) days or more in any twelve (12) month period. For purposes of this Agreement, the term
“totally or permanently disabled” or “total or permanent disability” means Executive’s inability on
account of sickness or accident, whether or not job-related, to engage in regularly or to perform
adequately his assigned duties under this Agreement and Executive is qualified and eligible to
receive disability benefits under the disability policies maintained by the Company for Executive.


 


3









 





5.2 Death of Executive. Executive’s employment and this Agreement shall terminate
immediately upon the death of Executive.



5.3 Termination for Cause. The Company may terminate Executive’s employment and this
Agreement at any time for “Cause” (as hereinafter defined) immediately upon written notice to
Executive. As used herein, the term “Cause” shall mean that Executive shall have: (i) been
convicted of a felony; or (ii) committed an act of fraud, embezzlement, or breach of trust; or
(iii) committed an act of willful misconduct or gross negligence resulting in a material loss to
the Company; or (iv) materially violated any material written Company policy or rules of the
Company, unless cured by Executive within 30 days following written notice thereof to Executive; or
(v) refused to follow the reasonable written directions given by the Board or its designee or
materially breached any covenant or obligation under this Agreement or other agreement with the
Company, unless cured by Executive within 30 days following written notice thereof to Executive.



5.4 Resignation. Executive’s employment and this Agreement shall terminate on the
earlier of the date that is one (1) month following the written submission of Executive’s
resignation to the Company or the date such resignation is accepted by the Company.



5.5 Termination Without Cause. The Company may terminate Executive’s employment and
this Agreement without cause upon written notice to Executive. Termination “without cause” shall
mean termination of employment on any basis (including no reason or no cause) other than
termination of Executive’s employment hereunder pursuant to Sections 5.1, 5.2, 5.3, or 5.4.



5.6 Surrender of Records and Property. Upon termination of his employment with the
Company, Executive shall deliver promptly to the Company all credit cards, computer equipment,
cellular telephone, records, manuals, books, blank forms, documents, letters, memoranda, notes,
notebooks, reports, data, tables, calculations or copies thereof, that are the property of the
Company and that relate in any way to the business, strategies, products, practices, processes,
policies or techniques of the Company, and all other property, trade secrets and confidential
information of the Company, including, but not limited to, all documents that in whole or in part
contain any trade secrets or confidential information of the Company that in any of these cases are
in his possession or under his control, and Executive shall also remove all such information from
any personal computers that he owns or controls.




6. Compensation Upon the Termination of Executive’s Employment.



6.1 In the event that Executive’s employment and this Agreement are terminated pursuant to
Section 5.1 (Disability), 5.3 (Cause), or 5.4 (Resignation), then Executive shall be entitled to
receive Executive’s then current Base Salary through the date his employment is terminated, and
such other amounts that accrued prior to the termination date and are required to be paid to him
pursuant to any employee benefit plan in accordance with such plan and/or by law, but no other
compensation of any kind or amount.


 


4









 





6.2 In the event Executive’s employment and this Agreement are terminated pursuant to Section
5.2 (Death), Executive’s beneficiary or a beneficiary designated by Executive in writing to the Company, or in the absence of such beneficiary, Executive’s
estate, shall be entitled to receive Executive’s then current Base Salary through the end of the
month in which his death occurs, and such other amounts that accrued prior to the termination date
and are required to be paid to him pursuant to any employee benefit plan in accordance with such
plan and/or by law, but no other compensation of any kind or amount.



6.3 Unless Section 7 applies, in the event Executive’s employment and this Agreement are
terminated by the Company pursuant to Section 5.5 (Without Cause) or by Executive for “Good Reason”
(as defined below), subject to Section 8 below, Executive shall receive accelerated vesting for
twelve (12) months from the date of Executive’s termination for all stock options granted by the
Company to Executive before or after the Commencement Date, and extension of the option exercise
period for an additional twelve (12) months beyond the period set forth in the governing option
documents for such exercise, provided, however, that the period for exercise of such stock options
shall not be extended beyond the date on which they would have terminated had Executive continued
to be employed by the Company. Executive shall receive no other compensation or benefits of any
kind.



6.4 The provisions of this Section 6 shall not affect Executive’s participation in or
terminating distributions and vested rights under, any pension, profit sharing, insurance or other
employee benefit plan of the Company to which Executive is entitled pursuant to the terms of such
plans.



7. Change in Control. In the event a Change in Control (as defined below) occurs
and, in the twelve month period preceding or following the Change in Control, Executive’s
employment and this Agreement are terminated by the Company or its successor, assigns or transferee
pursuant to Section 5.5 (Without Cause) or by Executive for “Good Reason” (as defined below), then
upon the occurrence of the last of these conditions (the “Trigger Date”), subject to Section 8
below, one hundred percent (100%) of Executive’s unvested options (whether granted before or after
the Commencement Date) as of the Trigger Date, shall automatically vest as of the Trigger Date and
the exercise period for all such stock options shall be extended an additional twelve (12) months
(but in any case not beyond the date on which they would have terminated had Executive continued to
be employed by the Company).



7.1 Definition of Change in Control. For purposes of this Agreement, a “Change in
Control” shall be deemed to have occurred if, at any time during the Term, any of the following
events occurs:



7.1.1 if the Company does not have a class of securities registered under Section 12 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”):




7.1.1.1 any person, as that term is used in Section 13(d) and Section 14(d)(2) of the
Exchange Act, becomes a beneficial owner (as defined in Rule 13d-3 under the Exchange Act or
any successor rule or regulation), directly or indirectly, of securities of the Company
representing 50% or more of the combined voting power of the Company’s then outstanding
Voting Stock, as defined below, provided, however, that for purposes of this
paragraph, the term “person” shall exclude (A) a trustee or other fiduciary holding
securities under an employee benefit plan of the Company or any of its subsidiaries, (B) a person who beneficially owns 25% or more of the Company’s
outstanding Voting Stock on the Effective Date, or (C) any person who becomes such a
beneficial owner in connection with a bona fide financing transaction.


 


5









 






7.1.1.2 the Company is merged, consolidated or reorganized into or with another
corporation or other legal person (an “Acquiring Person”) or securities of the Company are
exchanged for securities of an Acquiring Person, and as a result of such merger,
consolidation, reorganization or exchange less than a majority of the combined voting power
of the then outstanding securities of the Acquiring Person immediately after such
transaction is held, directly or indirectly, in the aggregate by the holders of securities
entitled to vote generally in the election of directors (“Voting Stock”) of the Company
immediately prior to such transaction;




7.1.1.3 the Company, in any transaction or series of related transactions, sells or
otherwise transfers, directly or indirectly, all or substantially all of its assets, on a
consolidated basis, to an Acquiring Person, and less than a majority of the combined voting
power of the then outstanding securities of the Acquiring Person immediately after such sale
or transfer is held, directly or indirectly, in the aggregate by the holders of Voting Stock
of the Company immediately prior to such sale or transfer; or




7.1.1.4 during any period of two consecutive years, individuals who at the beginning of
any such period constitute the directors of the Company cease for any reason to constitute
at least a majority thereof, unless the election, or the nomination for election by the
Company’s stockholders, of each director of the Company first elected during such period was
approved by at least a majority vote of the directors of the Company then still in office
who were directors of the Company at the beginning of any such period;




or



7.1.2 if the Company has a class of securities registered under Section 12 of the Exchange
Act:




7.1.2.1 any person, as that term is used in Section 13(d) and Section 14(d)(2) of the
Exchange Act, becomes, is discovered to be, or files a report on Schedule 13D or 14D-1 (or
any successor schedule, form or report) disclosing that such person is, a beneficial owner
(as defined in Rule 13d-3 under the Exchange Act or any successor rule or regulation),
directly or indirectly, of securities of the Company representing 25% or more of the
combined voting power of the Company’s then outstanding Voting Stock, provided,
however, that for purposes of this paragraph, the term “person” shall exclude (A) a trustee
or other fiduciary holding securities under an employee benefit plan of the Company or any
of its subsidiaries, (B) a person who becomes such a beneficial owner in connection with
the Company’s initial public offering of common stock or (C) any person who was a
shareholder of the Company immediately prior to the Company’s initial public offering of
common stock; or


 


6









 






7.1.2.2 any of the events described in Sections 7.1.1.2, 7.1.1.3 or 7.1.1.4 (the latter
being modified to refer to such a change of a majority of the Board of Directors during any
one year period).



Notwithstanding the foregoing, a transaction shall not constitute a Change in Control if its sole
purpose is to change the state of the Company’s incorporation or to create a holding company that
will be owned in substantially the same proportions by the persons who held the Company’s
securities immediately before such transaction.



7.2 Definition of Good Reason. As used in this Agreement, “Good Reason” means any of
the following: (i) a material reduction in Executive’s title, status, authority, or responsibility
at the Company, provided that a reduction of Executive to the title, authority and responsibilities
of Chief Operating Officer or any other “C level” office relating to a principal business function
or unit shall not of itself constitute Good Reason; or (ii) a material reduction in the salary or
other benefits in effect for the Executive, provided comparable reductions have not been made in
the salary or other benefits of the other members of senior management of the Company; or (iii)
except with Executive’s prior written consent, relocation of Executive’s principal place of
employment to a location more than 25 miles from the Company’s executive offices in Tucson,
Arizona; or (iv) ) any breach by the Company of its material obligations under this Agreement
unless such breach is cured within 30 days after written notice of breach from Executive.



8. Release. As a condition precedent to the Company’s obligation to provide Executive
with the acceleration of vesting of non-vested Stock Options as set forth in Section 6.3 or Section
7, Executive must first execute and deliver to the Company a mutual legal release in the form
attached hereto as Exhibit A, with such changes as the Company deems necessary in order to
maintain the breadth of such release in the event of changes in applicable laws, rules or
regulations, it being the intent of the parties that the release be as broad as possible.



9. Ventures. If, during the Term of this Agreement, Executive is engaged in or
associated with the planning or implementing of any project, program, or venture involving the
Company and a third party or parties, all rights in the project, program, or venture shall belong
to the Company and shall constitute a corporate opportunity belonging exclusively to the Company.
Except as approved in writing by the Board, Executive shall not be entitled to any interest in such
project, program, or venture or to any commission, finder’s fee, or other compensation in
connection therewith other than the Base Salary to be paid to Executive as provided in this
Agreement.




10. Restrictions.



10.1 Definitions. For purposes of this Agreement, the following terms shall have the
following meanings:



10.1.1 “Trade Secrets” means information that is not generally known about the Company
or its business, including without limitation about its products, recipes, projects, designs,
developmental or experimental work, computer programs, data bases, know-how, processes, business
partners, manufacturers, customers, suppliers, business plans,



 


7









 






marketing plans and strategies, financial or personnel information, and information obtained
from third parties under confidentiality agreements. “Trade Secrets” also means formulas,
patterns, compilations, programs, devices, methods, techniques, or processes that derive
independent economic value, actual or potential, from not being generally known to the public or to
other persons who can obtain economic value from its disclosure or use, and is the subject of
efforts that are reasonable under the circumstances to maintain its secrecy. In particular, the
parties agree and acknowledge that the following list, which is not exhaustive and is to be broadly
construed, enumerates some of the Company’s Trade Secrets, the disclosure of which would be
wrongful and would cause irreparable injury to the Company: (i) pharmaceutical manufacturing; (ii)
formulation technology; (iii) pricing information; (iv) product development, marketing, sales,
customer, manufacturer and supplier information related to any Company product or service available
commercially or in any stage of development during Executive’s employment with the Company; and (v)
Company marketing and business strategies, ideas, and concepts. Executive acknowledges that the
Company’s Trade Secrets were and are designed and developed by the Company at great expense and
over lengthy periods of time, are secret, confidential, and unique, and constitute the exclusive
property of the Company.



10.1.2 “Restricted Field” means the business of developing, manufacturing, licensing
and selling (i) treatment of vascular thrombosis comprising thrombolytic drugs with or without
bubbles and ultrasound, and (ii) oxygen delivery with bubbles or fluorocarbon emulsions.



10.1.3 “Non-Competition Period” means a period of 12 months after the termination of
Executive’s employment with the Company unless a court of competent jurisdiction determines that
that Period is unenforceable under applicable law because it is too long, in which case the
Non-Competition Period shall be for the longest of the following periods that the court determines
is reasonable under the circumstances: 11 months, 10 months, 9 months, 8 months, 7 months, or 6
months after the termination of Executive’s employment with the Company.



10.1.4 “Business Territory” means the entire United States, unless a court of
competent jurisdiction determines that that geographic scope is unenforceable under applicable law
because it is too broad, in which case the Business Territory shall be amended by eliminating
geographical areas and states from the following list until the Business Territory is determined to
be reasonable: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware,
District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky,
Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana,
Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota,
Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas,
Utah, Vermont, Virginia, Washington, Washington, District of Columbia, West Virginia, Wisconsin,
Wyoming, Pima County, Arizona, Maricopa County, Arizona, Tucson, Arizona, Phoenix, Arizona. The
parties acknowledge and agree that if any of the geographic areas or States listed above are
required by law to be eliminated, it would be fair and appropriate to do so in the inverse order of
the volume of revenue received or projected to be received by the Company from such area or State
at the time of determination.


 


8









 





10.1.5 “Non-Solicitation Period” means a period of 12 months after the termination of
Executive’s employment with the Company.



10.2 Non-Disclosure Obligations. Executive shall not at any time during the period
specified in Section 4.A. of the Invention and Confidential Information Agreement attached hereto
as Exhibit B, without the express written consent of a superior officer or the Board of the
Company, publish, disclose, or divulge to any person, firm or corporation, or use directly or
indirectly for the Executive’s own benefit or for the benefit of any person, firm, corporation or
entity other than the Company, any Trade Secrets of the Company.



10.3 Non-Competition Obligations. Executive acknowledges the substantial amount of
time, money, and effort that the Company has spent and will spend in developing its products and
other strategically important information (including Trade Secrets), and agrees that during
Executive’s employment with the Company hereunder and during the Non-Competition Period, Executive
will not, alone or with others, directly or indirectly, as an employee, agent, consultant, advisor,
owner, manager, lender, officer, director, employee, partner, stockholder, or otherwise, engage in
any Restricted Field activities in the Business Territory, nor have any such relationship with any
person or entity that engages in Restricted Field activities in the Business Territory; provided,
however, that nothing in this Agreement will prohibit Executive from owning a passive investment of
less than one percent of the outstanding equity securities of any company listed on any national
securities exchange or traded actively in any national over-the-counter market so long as Executive
has no other relationship with such company in violation of this Agreement. The Non-Competition
Period set forth in this Section 10.3 shall be tolled during any period in which the Executive is
in breach of the restriction set forth in this Section 10.3. 



10.4 Agreement Not to Solicit Customers. Executive agrees that during Executive’s
employment with the Company hereunder and during the Non-Solicitation Period, Executive will not,
either directly or indirectly, on Executive’s own behalf or in the service or on behalf of others,
solicit, divert, or appropriate, or attempt to solicit, divert, or appropriate, to any business
that engages in Restricted Field activities in the Business Territory (i) any person or entity
whose account with the Company was sold or serviced by or under the supervision of Executive during
the twelve (12) months preceding the termination of such employment, or (ii) any person or entity
whose account with the Company has been directly solicited at least twice by the Company within the
year preceding the termination of Executive’s employment (the “Customers”). The Non-Solicitation
Period set forth in this Section 10.4 shall be tolled during any period in which the Executive is
in breach of the restriction set forth in this Section 10.4.



10.5 Agreement Not to Solicit Employees. Executive agrees that during Executive’s
employment with the Company hereunder and during the Non-Solicitation Period, Executive will not,
either directly or indirectly, on Executive’s own behalf or in the service or on the behalf of
others solicit, divert, or hire away, or attempt to solicit, divert, or hire away any person then
employed by the Company, nor encourage anyone to leave the Company’s employ. The Non-Solicitation
Period set forth in this Section 10.5 shall be tolled during any period in which the Executive is
in breach of the restriction set forth in this Section 10.5.



10.6 Defamatory Statements. Executive agrees that during Executive’s employment with
the Company hereunder and thereafter, he will not, either directly or indirectly, defame the reputation, character, or image of the Company or its products, services,
employees, directors, or officers.


 


9









 





10.7 Reasonableness. Executive and the Company agree that the covenants set forth in
this Agreement are appropriate and reasonable when considered in light of the nature and extent of
the Company’s business. Executive further acknowledges and agrees that: (i) the Company has a
legitimate interest in protecting the Company’s business activities and its current, pending, and
potential Trade Secrets; (ii) the covenants set forth herein are not oppressive to Executive and
contain reasonable limitations as to time, scope, geographical area, and activity; (iii) the
covenants do not harm in any manner whatsoever the public interest; (iv) Executive’s chosen
profession, trade, or business is in manufacturing, developing, and marketing pharmaceutical drugs,
products and devices (the “Profession”); (v) the Restricted Field is only a very small or limited
part of the Profession, and Executive can work in many different jobs in Executive’s Profession
besides those in the Restricted Field; (vi) the covenants set forth herein do not completely
restrain Executive from working in Executive’s Profession, and Executive can earn a livelihood in
Executive’s Profession without violating any of the covenants set forth herein; (vii) Executive has
received and will receive substantial consideration for agreeing to such covenants, including
without limitation the consideration to be received by Executive under this Agreement; (viii) if
Executive were to work for a competing company that engages in activities in the Restricted Field,
there would be a substantial risk that Executive would inevitably disclose Trade Secrets to that
company; (ix) the Company competes with other companies that engage in Restricted Field activities
in the Business Territory, and if Executive were to engage in prohibited activities in the
Restricted Field within the Business Territory, it would harm the Company; (x) the Company expends
considerable resources on hiring, training, and retaining its employees and if Executive were to
engage in prohibited activities during the Non-Solicitation Period, it would harm the Company; and
(xi) the Company expends considerable resources acquiring, servicing, and retaining its Customers
and if Executive were to engage in prohibited activities during the Non-Solicitation Period, it
would harm the Company.



11. Other Agreements. Executive reaffirms Executive’s obligations set forth in the
Employee Agreement Concerning Invention Assignment Non-Disclosure and Non-Competition attached
hereto as Exhibit B, which Executive has previously executed and delivered; provided, that
in the event of any inconsistency between Exhibit B and the terms of Section 10 above, the
terms of Section 10 shall be controlling. Executive further acknowledges and agrees that he will
comply with all other Company policies and procedures. The terms of any Indemnity Agreement
between the Executive and Company will also continue in full force and effect.



12. Assignment. This Agreement shall not be assignable, in whole or in part, by
either party without the written consent of the other party, except that the Company may, without
the consent of Executive, assign its rights and obligations under this Agreement to any
corporation, firm or other business entity (i) with or into which the Company may merge or
consolidate, (ii) to which the Company may sell or transfer all or substantially all of its assets
or (iii) of which at least a majority of the equity investment and of the voting control is owned,
directly or indirectly, by, or is under common ownership with, the Company. Upon such assignment
by the Company, the Company shall exercise commercially reasonable efforts to obtain the assignees’
written agreement enforceable by Executive to assume and perform, from and after the date of such assignment, the terms, conditions, and provisions imposed by this
Agreement upon the Company.


 


10









 






13. Other Provisions.



13.1 Governing Law. This Agreement is made under and shall be governed by and
construed in accordance with the laws of the State of Arizona without reference to conflicts of law
provisions thereof.



13.2 Injunctive Relief. Executive agrees that it would be difficult to compensate the
Company fully for damages for any violation of the provisions of this Agreement. Accordingly,
Executive specifically agrees that the Company shall be entitled to temporary and permanent
injunctive relief to enforce the provisions of this Agreement. This provision with respect to
injunctive relief shall not, however, diminish the right of the Company to claim and recover
damages in addition to injunctive relief.



13.3 Prior Agreements. This Agreement and its exhibits contain the entire agreement
of the parties relating to the subject matter hereof and supersedes all prior agreements and
understandings with respect to such subject matter, and the parties hereto have made no agreements,
representations, or warranties relating to the subject matter of this Agreement which are not set
forth herein.



13.4 Withholding Taxes and Right of Offset. The Company may withhold from all
payments and benefits under this Agreement all federal, state, city, or other taxes as shall be
required pursuant to any law or governmental regulation or ruling. Executive agrees that the
Company may offset any payments owed to Executive pursuant to this Agreement by any amounts owed by
Executive to the Company.



13.5 Amendments. No amendment or modification of this Agreement shall be deemed
effective unless made in writing signed by Executive and the Company.



13.6 No Waiver. No term or condition of this Agreement shall be deemed to have been
waived nor shall there be any estoppel to enforce any provisions of this Agreement, except by a
statement in writing signed by the party against whom enforcement of the waiver or estoppel is
sought. Any written waiver shall not be deemed a continuing waiver unless specifically stated,
shall operate only as to the specific term or condition waived, and shall not constitute a waiver
of such term or condition for the future or as to any act other than that specifically waived.



13.7 Severability. To the extent any provision of this Agreement shall be invalid or
unenforceable, it shall be considered deleted from this Agreement and the remainder of such
provision and of this Agreement shall be unaffected and shall continue in full force and effect.



13.8 Indemnification. Executive shall be entitled as an officer and director to be
indemnified by the Company under the Organizational Documents, as set forth therein, and to receive
the benefits, if any, of any director and officer liability insurance obtained by the Company in its discretion from time to time, subject to the terms, provisions and conditions
of any such insurance.


 


11









 





13.9 Headings. The headings in this Agreement are included solely for reference
purposes and shall not be considered in the interpretation or construction of this Agreement.



13.10 Notices. All notices, requests, demands and other communications under this
Agreement shall be in writing and shall be delivered personally, by overnight courier or similar
means, by United States certified or registered mail, return receipt requested, postage prepaid, or
sent by facsimile transmission with written confirmation of receipt, at the addresses specified
below or such other addresses as the parties may designate by like notice. Any such notice shall
be effective upon receipt if delivered personally, by overnight courier or by United States
certified or registered mail, or on the next business day following transmittal if sent by
facsimile transmission.



	 	 	 	 	 
	 

	 	If to the Company:
	 	ImaRx Therapeutics, Inc.
	 

	 	 	 	1635 East 18th Street
	 

	 	 	 	Tucson, AZ 85719 
	 

	 	 	 	Attn: Chairman of the Board
	 

	 	 	 	Telephone: 520-770-1259 
	 

	 	 	 	Facsimile: 520-791-2437 
	 
	 	 	 	 
	 

	 	copy to:
	 	DLA Piper
	 

	 	 	 	701 Fifth Ave., Suite 7000 
	 

	 	 	 	Seattle, Washington 98104 
	 

	 	 	 	Attn: John M. Steel, Esq.
	 

	 	 	 	Telephone: (206) 839-4800 
	 

	 	 	 	Facsimile: (206) 839-4801 
	 
	 	 	 	 
	 

	 	If to Executive:
	 	Bradford A. Zakes
	 
	 	 	 	 
	 

	 	 	 	Telephone 520-975-5024 






13.11 No Mitigation Obligation. It will be difficult, and may be impossible, for
Executive to find reasonably comparable employment following the termination of Executive’s
employment with the Company, and the noncompetition covenant contained in Section 10 hereof will
further limit the employment opportunities for Executive. Accordingly, the parties hereto
expressly agree that the payments provided for in Section 6.3 and Section 7 by the Company to
Executive will be liquidated damages, and that Executive shall not be required to seek other
employment, or otherwise, to mitigate any payment provided for hereunder.



13.12 Remedies Cumulative. Remedies under this Agreement of either party hereto are
in addition to any remedy or remedies to which such party is entitled or may become entitled at law
or in equity.


 


12









 





13.13 Attorneys’ Fees. In the event suit is brought to enforce the terms of this
Agreement or to collect any moneys due hereunder, or to collect money damages for breach hereof,
the prevailing party shall be entitled to recover, in addition to any other remedy, reimbursement
for reasonable attorneys’ fees, court costs, costs of investigation and other related expenses
incurred in connection therewith.



13.14 Counterparts. This Agreement may be executed in any number of counterparts, all
such counterparts shall be deemed to constitute one and the same instrument, and each of said
counterparts shall be deemed an original hereof.



13.15 Survivability. Sections 4.3, 6, 7, 8, 10 and 13 of this Agreement shall survive
the termination of this Agreement and the termination of Executive’s employment with the Company.



IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first set
forth above.



	 	 	 	 	 	 	 
	 	 	“Company”:	 	ImaRx Therapeutics, Inc.
	 
	 	 	 	 
	 
	 	 	 	/s/
Richard Love 
	 	 	 	 	 
	 

	 	 	 	By:	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name:	 	Richard Love 
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:	 	Chairman 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	“Executive”:	 	/s/ Bradford A. Zakes 
	 	 	 	 	
 
	 	 	 	 	Bradford A. Zakes







 


13









 







Exhibit A




Form of Release




[Needs to be attached]



 


 









 





Exhibit B




Employee Agreement Concerning Invention Assignment

Non-Disclosure and Non-Competition

[Needs to be attached]